FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. DRI
8. ULS
9. AWK
10. USO

Go back to FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 123.89 -0.55 (0.44%)
Previous Close $124.44    52 Week High $118.49 
Open $125.72    52 Week Low $55.00 
Day High $126.00    P/E N/A 
Day Low $123.07    EPS $-0.56 
Volume 1,210,010       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1183.46 +1.57 (0.13%)
Previous Close $1181.89    52 Week High $88.16 
Open $1185.32    52 Week Low $67.88 
Day High $1190.00    P/E 273.95 
Day Low $1160.84    EPS $4.32 
Volume 1,924,379